Royalties payable Royalties Payable Represents the amount of royalties payable. Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Pay vs Performance Disclosure [Line Items] Schedule of Accrued and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued and other current liabilities Total accrued and other current liabilities Accrued Liabilities, Current Projected cash flows period Fair Value Inputs Cash Flows Estimated Period Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value. Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and development expense Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent License Agreements Related Party Transaction [Line Items] Stock option grant term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Royalties Accrued Royalties, Current Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc. Represents details pertaining to Syros Pharmaceuticals, Inc with whom we have entered into a target discovery, research collaboration and option agreement. Number of program targets Number Of Program Targets Represents the number of program targets identified. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP Stock Issued During Period, Value, Stock Options And Restricted Stock Units Exercised And Employee Stock Purchase Plan Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan. Effect of exchange rates on cash, cash equivalents, restricted cash and investments Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Shares Performance Shares [Member] Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Released (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period Represents the number of shares of employee compensation programs, other than options, released during the period. Investment, Name [Axis] Investment, Name [Axis] Commitments and contingencies (Note 14) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Revenues Disaggregation of Revenue [Line Items] Operating lease right-of-use assets Operating lease right-of-use assets Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease. Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Accrued and Other Current Liabilities Accrued Liabilities, Current [Abstract] Upfront payment under license agreement License Agreement Upfront Payment Amount Paid Represents the amount of the upfront payment made under the license agreement. Geographical [Axis] Geographical [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Proceeds from issuance of common stock under stock plans Proceeds from Stock Plans Income Taxes Income Tax Disclosure [Text Block] Dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Concentration of risk Concentration Risk [Line Items] Total liabilities Financial Liabilities Fair Value Disclosure Customer [Axis] Customer [Axis] Schedule of Inventory Schedule of Inventory [Table Text Block] Tabular disclosure of carrying amount of inventories as of the balance sheet date. Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in USD per share) Diluted net income per share ( in USD per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Number of shares awarded for each RSU (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units Represents the number of shares awarded for each restricted share units. Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Estimated Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Schedule of RSU Award and PSU Activity Under the 2010 Stock Plan Schedule of RSU award and PSU activity under the 2010 Stock Plan [Table Text Block] Tabular disclosure represents the schedule of share based compensation other than stock options activity. Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair market value of our long term investments Investments, Fair Value Disclosure Weighted-average fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net income Net income Net Income (Loss) Attributable to Parent Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Grant date value of shares outstanding at the beginning of the period (in USD per share) Grant date value of shares at the end of the period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Payment of contingent consideration Payment of Contingent Consideration The cash outflow with regard to the contingent consideration during the period. PEMAZYRE PEMAZYRE Represents information pertaining to PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Employee Stock Purchase Plan Employee Stock [Member] Marketable securities-amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Current Customer D Customer D [Member] Represents information pertaining to the customer D. Stockholders’ equity: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Developmental And Regulatory Milestones Developmental And Regulatory Milestones [Member] Developmental And Regulatory Milestones Schedule of Calculation of Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Service cost Defined Benefit Plan, Service Cost Clinical related costs Accrued Clinical Related Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] RSU and PSU Activity Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Unrecognized tax benefits current and prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Additional milestone payments under the license agreement License Agreement Additional Milestone Payments Represents the additional milestone payments to be made under the license agreement. Accounts receivable Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Total inventory Inventory Net Current and Noncurrent Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories. Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Accounts Receivable Accounts Receivable [Member] Available Shares for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Unrealized gain (loss) on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Payments made during the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Measurement Frequency [Axis] Measurement Frequency [Axis] Royalties payable on net sales Increase (Decrease) in Royalties Payable Organization and Business Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Accrued Liabilities Accrued Liabilities [Member] Contractual maturity dates Debt Instrument, Term Retirement Benefits [Abstract] Retirement Benefits [Abstract] Purchase of long term investments Payments to Acquire Long-Term Investments Roll forward of Level 3 liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Upfront and immediate milestone payment to be received under license agreement License Agreement, Upfront Payment and Immediate Milestone Payment to be Received Represents the upfront and immediate milestone payment received under the license agreement. Europe Europe [Member] Location of costs excluding the service component Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Options, RSUs and PSUs granted (in shares) Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Granted Number of shares granted under an established share-based compensation plan. Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Research and Development Expense Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Outstanding stock options and awards Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchase of common stock under Stock Purchase Agreement (in shares ) Purchase Of Common Stock Under Stock Purchase Agreement Represents the purchase of common stock under Stock Purchase Agreement. Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Property and Equipment, gross Property, Plant and Equipment, Gross Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Valuation input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Investment in Syndax Investment in Syndax Represents investment information pertaining to Syndax Pharmaceuticals Inc. Operating lease liabilities Operating Lease, Liability, Current Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Marketable securities-allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Issuance of shares of Common Stock under the ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Thomas Tray [Member] Thomas Tray Reductions related to prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Entity Shell Company Entity Shell Company Long term investments Fair market long term investments Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property and equipment, net Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Syndax Syndax Represents member information pertaining to Syndax Pharmaceuticals Inc. Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, restricted cash and investments at beginning of period Cash, cash equivalents, restricted cash and investments at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Security Exchange Name Security Exchange Name Total assets Assets, Fair Value Disclosure Schedule of Valuation Assumptions Used for Valuation of Fair Value of Stock Compensation Granted Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. JAKAVI JAKAVI Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America. Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Percentage of units vesting at the end of each calendar year (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Share-based Payment Arrangement, Option Employee Stock Option Employee Stock Option [Member] Vesting period of recognition of the unrecognized compensation cost of nonvested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total costs and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrecognized compensation cost for nonvested option (in dollars) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One GVHD GVHD [Member] Represents information pertaining to GVHD, an Graft-Versus-Host Disease field. Accrued and other liabilities Accrued Liabilities and Other Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] MacroGenics MacroGenics Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement. Stock Compensation Share-Based Payment Arrangement [Text Block] Development, Regulatory and Commercialization Milestones Development, Regulatory and Commercialization Milestones Represents development regulatory and commercialization milestones. Basis of presentation Basis of Accounting, Policy [Policy Text Block] Other, net Other Noncash Income (Expense) Stock Options Weighted Average Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Vijay Iyengar [Member] Vijay Iyengar Business Acquisition [Axis] Business Acquisition [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Restricted cash Restricted Cash, Noncurrent Other current liabilities Other Liabilities, Current Common stock held from investment (in shares) Investment Owned, Balance, Shares Income Statement [Abstract] Income Statement [Abstract] ICLUSIG ICLUSIG Represents information pertaining to ICLUSIG, a kinase inhibitor. Raw materials Inventory, Raw Materials, Net of Reserves Costs and expenses: Costs and Expenses [Abstract] Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Amortized Cost Debt securities (government) Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Number of independent programs License Agreement, Maximum Number Of Independent Programs Represents the maximum number of independent programs encompassed under the collaboration agreement. Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Amortization of actuarial losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Diluted Net Income (Loss) Per Share Earnings Per Share, Diluted [Abstract] ARIAD ARIAD Represents information pertaining to ARIAD Pharmaceuticals. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Achievement of Milestone [Domain] Achievement of Milestone [Domain] Different categories of achievement of milestones. Entity Tax Identification Number Entity Tax Identification Number Inventory Inventories - current Inventory, Net Purchases of marketable securities Payments to Acquire Marketable Securities Land Land [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Inventory Inventories-noncurrent Inventory, Noncurrent Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Product revenues, net Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] RSU and PSU Grant Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Stock compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] MorphoSys AG MorphoSys AG Represents member information pertaining to MorphoSys AG. Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Cost of Product Revenues Revenue from Contract with Customer [Policy Text Block] Commercialization Milestones Commercialization Milestones Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Released (in USD per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released Intrinsic Value Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options. Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] OPZELURA OPZELURA Represents information pertaining to OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib. Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Basic Net Income (Loss) Per Share Earnings Per Share, Basic [Abstract] Interest cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Employee Benefit Plans Retirement Benefits [Text Block] Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Foreign currency translation (loss) gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Incyte Incyte Represents member information pertaining to Incyte. Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Basic net income Net Income (Loss) Available to Common Stockholders, Basic Option Activity Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Period of lower average per unit cost of materials Period Of Deviation From Average, Cost Of Goods Sold Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Measurement Input Type [Domain] Measurement Input Type [Domain] Agenus Agenus Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement. Total liabilities Liabilities Volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Milestone and contract revenues Milestone and contract revenues Represents information pertaining to milestone and contract revenues. Vesting [Domain] Vesting [Domain] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount MiNK MiNK [Member] MiNK Defined contribution expense Defined Contribution Plan, Cost Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Building and leasehold improvements Building and leasehold improvements Represents information relating to building and leasehold improvements. Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock, $0.001 par value; 400,000,000 shares authorized; 224,101,839 and 222,746,719 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Sale of long term investments Proceeds from Sale of Long-Term Investments Anti-dilutive securities Earnings Per Share, Diluted, Other Disclosure [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Customer C Customer C [Member] Represents information pertaining to the customer C. Total current assets Assets, Current Debt securities (government) Debt securities (government) Debt securities issued by government or corporate business, banks and other entities with a promise of repayment. Other intangible assets, net Other Intangible Assets, Net U.S. Centers for Medicare and Medicaid Services U.S. Centers for Medicare and Medicaid Services [Member] U.S. Centers for Medicare and Medicaid Services Payment of finance lease liabilities Finance Lease, Principal Payments Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Schedule of Fair Value of Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Accounts receivable Accounts Receivable, after Allowance for Credit Loss All Individuals All Individuals [Member] Supplemental Schedule of Cash Flow Information Supplemental Cash Flow Information [Abstract] Litigation Case [Domain] Litigation Case [Domain] Interest income and other, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] PEO Name PEO Name Percentage of concentration risk Concentration Risk, Percentage Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Options, RSUs and PSUs cancelled (in shares) Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Canceled Number of shares canceled under an established share-based compensation plan. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Current Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Marketable securities—available-for-sale (amortized cost $290,583 and $292,580 as of September 30, 2023 and December 31, 2022, respectively; allowance for credit losses $0 as of September 30, 2023 and December 31, 2022) Debt Securities, Available-for-Sale, Current Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Depreciation and amortization Depreciation, Depletion and Amortization Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Milestone payment made under license agreement License Agreement Milestone Payment Amount Paid Represents the amount of the milestone payment made under the license agreement. Total stockholders’ equity Beginning Balance Ending Balance Equity, Attributable to Parent Accrued and Other Current Liabilities Accrued And Other Current Liabilities [Member] Primary financial statement caption encompassing accrued and other current liabilities. TABRECTA Royalty Revenues TABRECTA Royalty Revenues Represents information pertaining to TABRECTA royalty revenues, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Inventory incurred prior to FDA approval Inventory, Recorded as Research and Development Expense Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense. Net Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] GVHD GVHD Represents information pertaining to GVHD, an Graft-Versus-Host Disease field. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Average expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Payments for intangible assets Payments to Acquire Intangible Assets Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Weighted-average fair value assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Profit (loss) sharing ratio Collaboration Agreement Profit Loss Sharing Ratio Ratio of sharing profit and losses under the collaboration agreement. Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Decrease in unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Share-Based Payment Arrangement Share-Based Payment Arrangement [Member] Share conversion Subsidiary Stock, Conversion Ratio Number of parent common shares issuable upon conversion for each share of subsidiary stock to be converted. Title Trading Arrangement, Individual Title Weighted average price of options at the beginning of the period (in USD per share) Weighted average price of options at the end of the period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense PEMAZYRE Royalty Revenues PEMAZYRE Royalty Revenues [Member] PEMAZYRE Royalty Revenues Capital expenditures Payments to Acquire Other Productive Assets Common Stock Common Stock [Member] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Defined benefit pension gain, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Income Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Product royalty revenues Royalty [Member] Summary of Shares Available for Grant Schedule of Nonvested Share Activity [Table Text Block] Schedule of Roll Forward of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Sales and marketing Accrued Marketing Costs, Current Contingent consideration earned during the period but not yet paid Contingent consideration earned during the period but not yet paid Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination. Development and Regulatory Milestones Development and Regulatory Milestones Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Shares acquired due to distribution of dividend (in shares) Investment Owned, Balance, Shares Acquired Investment Owned, Balance, Shares Acquired Minimum Minimum [Member] Shares used in computing net income per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Liability Liability [Member] JAKAFI JAKAFI JAKAFI Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. Schedule of Option Activity Under the 2010 Stock Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Net income per share Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] OLUMIANT Royalty Revenues OLUMIANT Royalty Revenues Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis. Tax withholdings related to restricted and performance share vesting Payment, Tax Withholding, Share-Based Payment Arrangement Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income taxes paid Income Taxes Paid, Net Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred income tax asset Deferred Income Tax Assets, Net Schedule of Fair Value of Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Customer A, B, C, D, and E Customer A, B, C, D and E [Member] Represents information pertaining to the aggregate list of concentration customers. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Funding of future development costs (as a percent) License Agreement Percentage of Future Global Development Costs Funded Represents the percentage of future global development costs funded under the license agreement. Royalty payments on future global net sales (as a percent) Percentage Of Royalty Rate Payments Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other assets, net Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Average risk-free interest rates (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Basic (in USD per share) Basic net income per share ( in USD per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Construction in progress Construction Payable, Current Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Diluted net income Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Purchase price of common stock Equity Method Investment, Aggregate Cost Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Inventory, Current [Table] Inventory, Current [Table] Principles of Consolidation Consolidation, Policy [Policy Text Block] Issuance of shares of Common Stock for services rendered Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Sale and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Accrued and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] TABRECTA PROD SERV TABRECTA PRODUCT AND SERVICES [Member] TABRECTA PRODUCT AND SERVICES All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Achievement of Milestone [Axis] Achievement of Milestone [Axis] Represents information by different categories of achievement of milestones. Milestone payment, estimated useful life License Agreement Milestone Payment, Useful Life License Agreement Milestone Payment, Useful Life Cancelled (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Collaboration Partner A, B, C and D Collaboration Partner A, B, C and D Represents information pertaining to both the Collaboration partners A, B, C and D. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Tafasitamab Product and Service Tafasitamab Product and Service [Member] Tafasitamab Product and Service Current year expected contributions total Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive stock options and awards ( in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Customer E Customer E Represents information pertaining to the customer E. Unrealized (loss) gain on long term investments Unrealized (gain) loss on long term investments Unrealized gain (loss) on long term investments Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Amount recognized and received for the achievement of a predefined milestone License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement. Cost of Sales Cost of Sales [Member] (Gain) loss on change in fair value of acquisition-related contingent consideration Loss (gain) on change in fair value of acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finance lease liabilities Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Loss contingency accrual Loss Contingency Accrual Concentration of Credit Risk and Current Expected Credit Losses Concentration Risk Disclosure [Text Block] Stock compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Provision for income taxes Income Tax Expense (Benefit) Non-US Non-US [Member] Finished goods Inventory, Finished Goods, Net of Reserves Finance lease right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Accrued compensation Employee-related Liabilities, Current Vesting [Axis] Vesting [Axis] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name License Agreements License Agreements License Agreements Other comprehensive (loss) income Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Summary of marketable security portfolio Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Eli Lilly Eli Lilly Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement. Loss contingences, gross to net deduction percentage Loss Contingences, Gross To Net Deduction Percentage Loss Contingences, Gross To Net Deduction Percentage License Agreements License Agreements [Text Block] This element may be used to describe all significant license agreements of the reporting entity. Deferred income taxes Increase (Decrease) in Deferred Income Taxes Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other Intangible Assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Issuance of shares of Common Stock for services rendered (in shares) Stock Issued During Period, Shares, Issued for Services Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Diluted (in shares) Weighted average shares used to compute diluted net income per share ( in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Leased assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Additional authorization (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Assumed annualized forfeiture rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate Represents the expected annualized forfeiture rate for options granted. Revenue, Product and Service Benchmark Revenue, Product and Service Benchmark [Member] Revenues Revenue from Contract with Customer [Text Block] Loss and (profit) sharing under collaboration agreements Collaboration Loss (Profit) Sharing Expense Collaboration Loss (Profit) Sharing Expense Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Regulatory Milestone Regulatory Milestone [Member] Regulatory Milestone Credit Concentration Risk Credit Concentration Risk [Member] Laboratory equipment Equipment [Member] Customer B Customer B [Member] Represents information pertaining to the customer B. Regulatory Milestones Regulatory Milestones Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved. Development Milestones Development Milestones Represents information pertaining to certain development events on the basis of which certain milestones are achieved. Stock compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition UNITED STATES UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Other liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] MINJUVI MINJUVI Represents information pertaining to MONJUVI/MINJUVI (tafasitamab-cxix). Milestone and contract revenues Milestone revenues Represents information pertaining to milestone revenue. Construction in progress Construction in Progress [Member] Sales allowances Provision for Loss on Contracts OLUMIANT OLUMIANT Baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). JAKAVI Royalty Revenues JAKAVI Royalty Revenues Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. ZYNYZ ZYNYZ [Member] ZYNYZ Net increase in cash, cash equivalents, restricted cash and investments Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Finance lease liabilities Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Cancelled (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Income from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Office equipment Office Equipment [Member] Revenues: Revenues [Abstract] Cost of product revenues (including definite-lived intangible amortization) Cost of Revenue Schedule of Concentration of Credit Risk Related to Collaborative Partners Schedules of Concentration of Risk by Risk Factor Related to Collaborative Partners [Table Text Block] Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Merus Merus Represents information pertaining to Merus N. V. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer A Customer A [Member] Represents information pertaining to the customer A. Summary of Marketable Securities Portfolio Debt Securities, Available-for-Sale [Table Text Block] Novartis Novartis Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement. Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member]